Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2015-01-18262,2015,VanDeusen 2015 BMC Infect Dis,900,"Option B+: HIV-infected pregnant women receive lifelong antiretroviral therapy beginning at their first pregnancy. Infants born to HIV+ women receive daily zidovudine (AZT) for the first 4-6 weeks of life VERSUS Option B: antiretroviral prophylaxis that begins early in gestation and continues through breastfeeding for women with a CD4 count above 350 cells/mm3, and lifetime antiretroviral therapy for women with a CD4 count below 350 cells/mm3. Infants born to HIV+ women receive daily zidovudine (AZT) for the first 4-6 weeks of life IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Ghana; Other- HIV-infected pregnant women in Ghana, who are pregnant with their first child.",25887574,"Specific disease- HIV; Age- Adult; Gender- Female; Country- Ghana; Other- HIV-infected pregnant women in Ghana, who are pregnant with their first child.",Option B+: HIV-infected pregnant women receive lifelong antiretroviral therapy beginning at their first pregnancy. Infants born to HIV+ women receive daily zidovudine (AZT) for the first 4-6 weeks of life,"Cost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, Ghana.","Option B: antiretroviral prophylaxis that begins early in gestation and continues through breastfeeding for women with a CD4 count above 350 cells/mm3, and lifetime antiretroviral therapy for women with a CD4 count below 350 cells/mm3. Infants born to HIV+ women receive daily zidovudine (AZT) for the first 4-6 weeks of life",NE
1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
